Supp. Materials and Methods
We designed oligonucleotide primers for each of the 48 exons of DOCK6 using the Primer3 software version 4.0.0 (http://primer3.ut.ee/) [Untergrasser et al., 2012] . Primer sequences and PCR conditions are available upon request. Sequencing was carried out using the BigDye Terminator Cycle Sequencing Kit v3.1 on an ABI 3500xl automated capillary sequencer (Applied Biosystems, Cheshire, UK). Obtained sequences were compared with the reference sequence (NM_020812.3) using the Sequence Pilot software v4.0.1 (JSI Medical Systems GmbH, Kippenheim, Germany). Pathogenicity of all observed sequence variants was assessed using various online prediction tools. For splice site prediction we utilized the following bioinformatic tools:
-BDGP (Berkeley Drosophila Genome Project) last updated 28 July 2014, Human or other, minimum scores for splice sites: 0.1 http://www.fruitfly.org/seq_tools/splice.html [Reese et al., 1997] -NetGene2
Version 2.4, Human http://www.cbs.dtu.dk/services/NetGene2/ [Brunak et al., 1991] Missense mutations were rated using the following: -PolyPhen-2 (Polymorphism Phenotyping v2) Version 2.2.2, NP_065863.2 http://genetics.bwh.harvard.edu/pph2/ [Adzhubei et al., 2010] -SIFT Human Protein (Sorting Intolerant From Tolerant) page last modified: August 2011, Ensembl 63, ENSP00000294618 http://sift.jcvi.org/www/SIFT_enst_submit.html [Ng and Henikoff, 2003] -MutPred (Mutation Prediction) last modified 02 Feb 2014, NP_065863.2 http://mutpred.mutdb.org [Li et al., 2009] -GERP (Genomic Evolutionary Rate Profiling) hg19, http://mendel.stanford.edu/SidowLab/downloads/gerp/index.html [Cooper et al., 2005] All variants were checked regarding their appearance/frequency in EVS (Exome Variant Server, Gene ID: 57572, GRCh37, http://evs.gs.washington.edu/EVS/, [Exome Variant Server, 2015]) and TGP (1000 Genomes Project, http://www.1000genomes.org/home, [1000 Genomes Project Consortium et al., 2010 [Altschul et al., 1990] https://mutalyzer.nl/) [Wildeman et al., 2008] .
A focused MLPA assay including probes for DOCK6 exons 40 through 48 was developed (probe sequences available upon request) for copy number determination of the terminal DOCK6 exons in a family where PCR amplification of exons 42 to 48 failed in the index patient.
We have established a collection of all mutations and selected unclassified variants in the DOCK6 gene (http://databases.lovd.nl/shared/variants/DOCK6) at the Leiden Open Variation Database (LOVD, version 3.0) [Fokkema et al., 2011] , as well as all available phenotype data of patients that were designated as AOS2 both clinically and genotypically (http://databases.lovd.nl/shared/individuals/DOCK6). To date, the database contains 17 different DOCK6 mutations and phenotype data from 18 individuals. 
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Family 10 __________________________________________________________ Pedigrees representing DOCK6 mutation positive families. Affected individuals are indicated by filled symbols. All available genotype data is added and sequence electropherograms are shown. Family 2: RNA analysis is additionally displayed. Family 6: in the index patient the wild type allele is drastically under-represented regarding the heterozygous c.5939+2T>C splice site mutation. We assume this to be caused by a technical artefact due to very poor DNA quality. Family 9: MLPA results (multiplex ligation-dependent probe amplification) are shown. hom, homozygous; het, heterozygous; WT, wild type; ?* patient not listed in Table 1 due to lack of clinical data and not genetically analyzed due to lack of adequate material. Various online prediction tools were used to evaluate mutation effects. PolyPhen-2: score >0.909, probably damaging; score 0.447 -0.908, possibly damaging; score ≤0.446, benign; sensitivity: True Positive Rate, the chance that the mutation is classified as damaging when it is indeed damaging; specificity: 1 -False Positive Rate, the chance that the benign mutation is correctly classified as benign [Adzhubei et al., 2013] . SIFT: score = normalized probability that the amino acid change is tolerated; ≤0.05, damaging; >0.05, tolerated; median information content: maximum 4.32, indicates complete conservation at this position; minimum 0.00, indicates a position where all 20 amino acids are tolerated; ideally between 2.75 and 3.5 [Ng and Henikoff, 2003] . MutPred: general score; ranges between 1.000 (deleterious mutation) and 0.000 (benign). GERP: ranges from 6.17 (highly conserved amino acid residue) to -12.3 (not conserved). This donor splice site alteration at position +5 in intron 32 was detected in compound heterozygosity with a frameshift mutation in family 7. The online tools BDGP (Berkeley Drosophila Genome Project) and NetGene2 predict this nucleotide exchange to impair the regular splice donor site at the border between exon 32 and intron 32. The indicated probability scores refer to the authentic splice site.
Supp. Table S4 Various online prediction tools were used to evaluate mutation effects. PolyPhen-2: score >0.909, probably damaging; score 0.447 -0.908, possibly damaging; score ≤0.446, benign; sensitivity: True Positive Rate, the chance that the mutation is classified as damaging when it is indeed damaging; specificity: 1 -False Positive Rate, the chance that the benign mutation is correctly classified as benign
